Filing Scope and Business Context
The provided filing is Aileron Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, not Rein Therapeutics, Inc. Investors should verify the company identity before relying on this summary. Aileron was a clinical-stage oncology company developing ALRN-6924, an MDM2/MDMX dual inhibitor intended primarily as a chemoprotective agent for patients with p53-mutated cancers. The filing was signed March 20, 2023.
Aileron completed a 1-for-20 reverse stock split on November 10, 2022. Reported share and per-share amounts reflect the split retrospectively.
2022 Financial Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $18.0 million | $17.0 million | +$1.0 million |
| General and administrative expense | $9.7 million | $9.6 million | +$0.1 million |
| Total operating expenses | $27.6 million | $26.6 million | +$1.0 million |
| Loss from operations | $27.6 million | $26.6 million | Loss increased $1.0 million |
| Other income, net | $0.3 million | $0.4 million | -$0.1 million |
| Net loss | $27.3 million | $26.2 million | Loss increased $1.2 million |
| Basic and diluted loss per share | $6.02 | $5.89 | Loss per share increased |
| Cash used in operating activities | $24.9 million | $23.8 million | Use increased $1.1 million |
The company had no product revenue and no marketed products. Profit margins are not meaningful because revenue was zero and the company remained loss-making. Stock-based compensation was $2.1 million in 2022, compared with $2.3 million in 2021.
Liquidity, Capitalization, Debt and Cash Flow
- Cash, cash equivalents and investments totaled $21.2 million at December 31, 2022, comprising $5.2 million of cash and cash equivalents and $16.0 million of investments.
- Total assets were $22.0 million, total liabilities were $3.4 million and stockholders’ equity was $18.6 million at year-end.
- The company reported no outstanding debt at December 31, 2022. Its Paycheck Protection Program loan was forgiven in 2021.
- Cash used in operations was $24.9 million. Investing activities provided $26.5 million, primarily from net sales and maturities of investments. Financing activities provided no cash in 2022.
- Management stated that year-end cash, cash equivalents and investments were expected to fund operating expenses for at least twelve months under its current operating plan, subject to the outcome and cost of strategic alternatives.
- The company nevertheless disclosed substantial doubt about its ability to continue as a going concern because of continuing losses, negative operating cash flow and uncertainty regarding strategic alternatives and future cash consumption.
- The company had $239.6 million of federal and $231.6 million of state net operating loss carryforwards, but maintained a full valuation allowance against deferred tax assets.
Material Changes Versus 2021
- Research and development expense increased primarily because spending on the Phase 1b breast cancer trial increased by $3.5 million, partly offset by lower spending on completed healthy-volunteer, small-cell lung cancer and non-small-cell lung cancer studies.
- Operating cash burn increased by approximately $1.1 million, while net loss increased by approximately $1.2 million.
- Investment balances declined from $42.3 million to $16.0 million, while cash and cash equivalents increased from $3.6 million to $5.2 million as the company repositioned its short-term liquidity.
- Unlike 2021, when financing activities generated $55.7 million from equity issuances, the company raised no financing in 2022.
- Shares outstanding increased modestly from 4.529 million to 4.541 million, excluding the retrospective effect of the reverse split.
Outlook, Strategic Actions and Risks
In February 2023, after reviewing initial data from the Phase 1b breast cancer trial, Aileron reported Grade 4 severe neutropenia and alopecia in trial participants. It terminated the trial and discontinued further development of ALRN-6924. The company also began evaluating an acquisition, merger, business combination, asset sale or other strategic transaction, with Ladenburg Thalmann & Co., Inc. as advisor. There was no established timetable or assurance that a transaction would occur or provide attractive terms.
The company planned to reduce its workforce from nine to three full-time employees, with completion expected in the second quarter of 2023. Estimated severance and termination-related costs were approximately $1.0 million to $1.1 million, expected to be recorded in the first quarter of 2023 and paid through the second quarter.
If a transaction cannot be completed, the board may consider dissolution, liquidation or bankruptcy protection. The amount and timing of any distribution to stockholders is uncertain and could be zero. The company expected operating expenses to decline materially after the program termination and workforce reduction, but cautioned that anticipated savings might not be realized and that trial close-out, strategic review, litigation, regulatory and other costs could exceed expectations.
- ALRN-6924 had not received marketing approval in the United States or elsewhere and had generated no commercial revenue.
- The company relied on third parties for manufacturing and clinical development activities and had paused manufacturing of ALRN-6924.
- The company’s ability to access equity financing was constrained: no 2022 ATM sales occurred, and sales under the Lincoln Park Capital facility were unavailable because the stock price was below the facility’s $6.00 floor price.
- The company regained compliance with Nasdaq’s $1.00 minimum bid-price requirement after the reverse stock split, but warned that continued listing was not assured.
- The company’s independent auditor issued an unqualified opinion but separately highlighted substantial doubt about going-concern status. Management reported effective disclosure controls and internal control over financial reporting at December 31, 2022.
Most Important Facts to Verify
- Entity identity: confirm whether the intended filing was for Rein Therapeutics or Aileron Therapeutics, because the supplied document names Aileron throughout.
- Going-concern status: review subsequent filings for cash consumption, financing, strategic transactions, liquidation plans or bankruptcy actions.
- Strategic alternatives: verify whether any acquisition, merger, asset sale or other transaction was completed and on what terms.
- Cash availability: reconcile the reported $21.2 million of cash, cash equivalents and investments with subsequent operating expenses, severance and trial close-out costs.
- Potential stockholder recovery: assess liabilities, reserves, transaction costs and contingent obligations before assuming that reported cash will be distributable to common stockholders.
- Clinical and intellectual property value: verify the status and market value of ALRN-6924 and related patent licenses after development was discontinued.